Neurimmune (Licensor)ALS TDI (Licensee)
Neurimmune and ALS Therapeutics LLC partnered to develop preclinical human antibodies from Neurimmune that target misfolded superoxide dismutase 1 (SOD1) for amyotrophic lateral sclerosis (ALS)
Tactic Pharma (Seller)Wilson Therapeutics (Buyer)
Wilson purchasing Decuprate (ATN-224) from Tactic.
Set Email Alert